| 초록 |
Objectives:
Data-driven drug discovery (D4) exploits a comprehensive set of ‘Big’ data in order to provide an efficient path to new drug development.
Methods: We present in silico chemical genomic approaches for target discovery & identification of drug repositioning (DR) candidates for cancer precision medicine. It is based on a recent large-scale dataset of ~20,000 drug-induced expression profiles in multiple cancer cell lines, which provides i) a global impact of transcriptional perturbation of both known targets and unknown off-targets, and ii) rich information on drug’s mode-of-action.
Results: Here, we present several cases for target discovery & drug repositioning (DR) based on large-scale drug-induced expression profiles, or CMAP.
Conclusions: .
|